Please login to the form below
Vizimpro
This page shows the latest Vizimpro news and features for those working in and with pharma, biotech and healthcare.
Tagrisso tops rival drugs on survival in first-line lung cancer
Takes fight to Pfizer's Vizimpro. AstraZeneca has the improvement in overall survival (OS) it needed for lung cancer therapy Tagrisso (osimertinib), as it tries to double down on its use ... NICE also judged that the drug would not eligible for inclusion
Latest news
-
AstraZenca to appeal NICE rejection of Tagrisso
The decision not to recommend Tagrisso coincided with NICE’s recommendation of Pfizer’s Vizimpro (dacomitinib) in the same patient population. ... However, NICE did acknowledge that Vizimpro had a higher incidence of side effects, so a lower dose
-
Pfizer’s Talzenna cleared for breast cancer in Europe
Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro (dacomitinib) for locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC).
-
Pfizer poaches cancer R&D head Jeff Settleman from Calico
That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to
-
Pfizer gets EU nod for Tagrisso rival Vizimpro
Five year survival still only 12%. Pfizer’s Vizimpro, a drug that could challenge AstraZeneca’s fast-growing Tagrisso in lung cancer, has been approved for marketing by the European Commission. ... Vizimpro (dacomitinib) has been approved in the EU
More from news
Approximately 5 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
In its 2019 reviews of Pfizer’s Vizimpro and Takeda’s Adcetris, NICE noted that EQ-5D “may not be sensitive to skin-related diseases” and may fail to fully capture
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
